Lars Gullestad

27.6k total citations · 3 hit papers
462 papers, 17.3k citations indexed

About

Lars Gullestad is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Molecular Biology. According to data from OpenAlex, Lars Gullestad has authored 462 papers receiving a total of 17.3k indexed citations (citations by other indexed papers that have themselves been cited), including 265 papers in Cardiology and Cardiovascular Medicine, 169 papers in Surgery and 84 papers in Molecular Biology. Recurrent topics in Lars Gullestad's work include Transplantation: Methods and Outcomes (104 papers), Cardiovascular Function and Risk Factors (63 papers) and Heart Failure Treatment and Management (57 papers). Lars Gullestad is often cited by papers focused on Transplantation: Methods and Outcomes (104 papers), Cardiovascular Function and Risk Factors (63 papers) and Heart Failure Treatment and Management (57 papers). Lars Gullestad collaborates with scholars based in Norway, Sweden and Denmark. Lars Gullestad's co-authors include Thor Ueland, Pål Aukrust, Arne Yndestad, Stig S. Frøland, Pål Aukrust, Jan Kristian Damås, John Kjekshus, Svein Simonsen, Erik Øie and Bente Halvorsen and has published in prestigious journals such as The Lancet, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Lars Gullestad

449 papers receiving 17.0k citations

Hit Papers

EUR Observational Researc... 2013 2026 2017 2021 2013 2016 2016 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. EUR Observational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)
    2013 588 citations Aldo P. Maggioni, Ulf Dahlström et al. European Journal of Heart Failure profile →
  2. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial
    2016 288 citations Ola Kleveland, Gabor Kunszt et al. profile →
  3. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial
    2016 271 citations Lars Aaberge, Svend Aakhus et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Lars Gullestad 8.5k 4.3k 4.2k 3.1k 2.1k 462 17.3k
Frank W. Sellke 7.1k 0.8× 5.8k 1.4× 5.9k 1.4× 2.7k 0.8× 1.3k 0.6× 575 22.7k
Nikolaus Marx 5.8k 0.7× 6.5k 1.5× 4.4k 1.0× 2.4k 0.8× 3.5k 1.7× 530 20.8k
Javier Dı́ez 12.0k 1.4× 4.7k 1.1× 3.2k 0.8× 1.5k 0.5× 1.6k 0.8× 407 19.8k
Dimitris Tousoulis 9.1k 1.1× 3.8k 0.9× 3.9k 0.9× 2.3k 0.7× 2.9k 1.4× 811 20.5k
Antonio Abbate 11.5k 1.4× 8.2k 1.9× 5.5k 1.3× 3.1k 1.0× 2.9k 1.4× 519 23.5k
Stefan Frantz 6.6k 0.8× 4.2k 1.0× 2.1k 0.5× 2.1k 0.7× 1.3k 0.6× 269 12.3k
Hiroyuki Tsutsui 11.7k 1.4× 7.1k 1.7× 2.8k 0.7× 1.8k 0.6× 1.8k 0.9× 645 22.4k
Hermann Haller 4.8k 0.6× 7.0k 1.6× 4.1k 1.0× 2.7k 0.9× 2.0k 1.0× 454 23.0k
Wiek H. van Gilst 11.8k 1.4× 3.6k 0.9× 2.8k 0.7× 1.5k 0.5× 1.0k 0.5× 475 20.4k
Elena Tremoli 6.3k 0.7× 3.3k 0.8× 3.9k 0.9× 1.9k 0.6× 1.9k 0.9× 482 17.1k

Countries citing papers authored by Lars Gullestad

Since Specialization
Citations

This map shows the geographic impact of Lars Gullestad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Gullestad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Gullestad more than expected).

Fields of papers citing papers by Lars Gullestad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Gullestad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Gullestad. The network helps show where Lars Gullestad may publish in the future.

Co-authorship network of co-authors of Lars Gullestad

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Gullestad. A scholar is included among the top collaborators of Lars Gullestad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Gullestad. Lars Gullestad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Myhre, Peder L., et al.. (2024). Changes in 6‐min walk test is an independent predictor of death in chronic heart failure with reduced ejection fraction. European Journal of Heart Failure. 26(12). 2608–2615. 1 indexed citations
2.
Woxholt, Sindre, Thor Ueland, Pål Aukrust, et al.. (2024). Effect of tocilizumab on endothelial and platelet-derived CXC-chemokines and their association with inflammation and myocardial injury in STEMI patients undergoing primary PCI. International Journal of Cardiology. 418. 132613–132613. 1 indexed citations
3.
4.
Andersen, Rune, S Birkeland, Morten Svalebjørg, et al.. (2023). Pulmonary endarterectomy and balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension: Comparison of changes in hemodynamics and functional capacity. Pulmonary Circulation. 13(1). e12199–e12199. 7 indexed citations
5.
Ofstad, Anne Pernille, Cathrine Brunborg, Odd Erik Johansen, et al.. (2023). Development of a Tool to Predict the Risk of Incident Heart Failure in a General Population: The HUNT for HF Risk Score. ESC Heart Failure. 10(5). 2807–2815. 3 indexed citations
6.
Remme, Espen W., Otto A. Smiseth, Richard Massey, et al.. (2023). Non-invasive myocardial work in aortic stenosis: validation and improvement in left ventricular pressure estimation. European Heart Journal - Cardiovascular Imaging. 25(2). 201–212. 5 indexed citations
7.
Vethe, Nils Tore, Kari Peersen, Morten Wang Fagerland, et al.. (2020). Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial. European Heart Journal - Cardiovascular Pharmacotherapy. 7(6). 507–516. 19 indexed citations
8.
George, Marc J., Ola Kleveland, Jorge García‐Hernández, et al.. (2020). Novel Insights Into the Effects of Interleukin 6 Antagonism in Non–ST‐Segment–Elevation Myocardial Infarction Employing the SOMAscan Proteomics Platform. Journal of the American Heart Association. 9(12). e015628–e015628. 17 indexed citations
9.
Ueland, Thor, Annika E. Michelsen, Judith Krey Ludviksen, et al.. (2019). Increased Complement Factor B and Bb Levels Are Associated with Mortality in Patients with Severe Aortic Stenosis. The Journal of Immunology. 203(7). 1973–1980. 8 indexed citations
10.
Kleveland, Ola, Thor Ueland, Gabor Kunszt, et al.. (2018). Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction. International Journal of Cardiology. 271. 1–7. 27 indexed citations
11.
Ueland, Thor, Pål Aukrust, Annika E. Michelsen, et al.. (2017). Immediate response in markers of inflammation and angiogenesis during exercise: a randomised cross-over study in heart transplant recipients. Open Heart. 4(2). e000635–e000635. 16 indexed citations
12.
Ueland, Thor, Ståle H. Nymo, Roberto Latini, et al.. (2013). CCL21 is Associated with Fatal Outcomes in Chronic Heart Failure: Data from CORONA and GISSI-HF Trials. European Journal of Heart Failure. 15(7). 747–755. 15 indexed citations
13.
Broch, Kaspar, Thor Ueland, Ståle H. Nymo, et al.. (2012). Soluble ST2 is Associated with Adverse Outcome in Patients with Heart Failure of Ischaemic Aetiology. European Journal of Heart Failure. 14(3). 268–277. 106 indexed citations
14.
Latini, Roberto, Lars Gullestad, Serge Masson, et al.. (2012). Pentraxin-3 in Chronic Heart Failure: The CORONA and GISSI-HF Trials. European Journal of Heart Failure. 14(9). 992–999. 80 indexed citations
15.
Solberg, Ole Geir, Thor Ueland, Ragnhild Wergeland, et al.. (2012). High-sensitive troponin T and N-terminal-brain-natriuretic-peptide predict outcome in symptomatic aortic stenosis. Scandinavian Cardiovascular Journal. 46(5). 278–285. 23 indexed citations
16.
17.
Maggioni, Aldo P., Ulf Dahlström, Gerasimos Filippatos, et al.. (2010). EUR Observational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot). European Journal of Heart Failure. 12(10). 1076–1084. 295 indexed citations
18.
Gjesdal, Ola, Satish Arora, Torbjørn Leivestad, et al.. (2009). Intra-Aortic Balloon Counterpulsation as a Bridge to Heart Transplantation does not Impair Long-Term Survival. European Journal of Heart Failure. 11(7). 709–714. 45 indexed citations
19.
Dahl, Christen P., Lars Gullestad, Børre Fevang, et al.. (2008). Increased Expression of LIGHT/TNFSF14 and its Receptors in Experimental and Clinical Heart Failure. European Journal of Heart Failure. 10(4). 352–359. 28 indexed citations
20.
Gullestad, Lars, Heather J. Ross, Khánh Hoàng, et al.. (1997). Importance of decreased heart rate in predicting transplant coronary artery disease. Clinical Transplantation. 11(6). 628–632. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frank W. Sellke Breakdown of academic impact, for papers by Nikolaus Marx Breakdown of academic impact, for papers by Javier Dı́ez Breakdown of academic impact, for papers by Dimitris Tousoulis Breakdown of academic impact, for papers by Antonio Abbate Breakdown of academic impact, for papers by Stefan Frantz Breakdown of academic impact, for papers by Hiroyuki Tsutsui Breakdown of academic impact, for papers by Hermann Haller Breakdown of academic impact, for papers by Wiek H. van Gilst Breakdown of academic impact, for papers by Elena Tremoli
Rankless by CCL
2026